AR030562A1 - Derivados de dibenzoazuleno, su uso y procedimientos para prepararlos. - Google Patents
Derivados de dibenzoazuleno, su uso y procedimientos para prepararlos.Info
- Publication number
- AR030562A1 AR030562A1 ARP010102339A ARP010102339A AR030562A1 AR 030562 A1 AR030562 A1 AR 030562A1 AR P010102339 A ARP010102339 A AR P010102339A AR P010102339 A ARP010102339 A AR P010102339A AR 030562 A1 AR030562 A1 AR 030562A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- represent
- formula
- substituted
- aryl
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 102000004127 Cytokines Human genes 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 2
- 102000000589 Interleukin-1 Human genes 0.000 abstract 2
- 108010002352 Interleukin-1 Proteins 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 101150020251 NR13 gene Proteins 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 206010054094 Tumour necrosis Diseases 0.000 abstract 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000003973 alkyl amines Chemical class 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000005907 alkyl ester group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 150000008064 anhydrides Chemical class 0.000 abstract 1
- 150000007860 aryl ester derivatives Chemical class 0.000 abstract 1
- 125000005110 aryl thio group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001735 carboxylic acids Chemical class 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- -1 cyano, amino Chemical group 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004970 halomethyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Derivados de dibenzoazuleno, sus sales y solvatos farmacéuticamente aceptables, representados por la formula (1), en donde X puede representar CH2 o un heteroátomo tal como O, S, S(=O), S(=O)2 o NR13, significa hidrogeno, alquilo C1-6, alquilcarbonilo C1-6, arilcarbonilo, arilsulfonilo o alquilsulfonilo C1-6 y R1, R2, R3, R4, R5, R6, R7, R8, R9, independientemente uno del otro, representan sustituyentes que pueden ser hidrogeno, halogenos, (fluor, cloro o bromo); o alquenilos, arilos, heteroarilos o alquilos C1-7, o pueden representar diferentes grupos: halometilo, ariloxi, hidroxi o alcoxi C1-7, alquilo C1-7 o ariltio, alquilsulfonilo C1-7, ciano, amino, aminas mono- y di- C1-7 sustituidas, derivados de grupo carboxílico (ácidos carboxílicos C1-7 y sus anhídridos, amidas C1-7 insustituidas, mono-, di-sustituidas, alquilo C1-7 o arilésteres), derivados C1-7 de grupo carbonilo (alquilo C1-7 o arilcarbonilos), y R10 puede representar sustituyentes tales como: alquilos C2-15, alquenilos C2-15, arilos, heteroarilos o alquinilos C2-15, haloalquilos C1-15, hidroxialquilos C1-15, alquiloxi C1-15, alquiltio C1-15, alquilcarbonilos C3-15, ácido alquilcarboxílico C2-15, alquilésteres C2-15, alquilsulfonilos C1-15, alquilarilsulfonilos C1-15, arilsulfonilos, y alquilaminas C1-15 representadas por la formula general (2): -(CH2)n-A donde n significa 1-15, y uno o más grupos metileno pueden ser sustituidos por un átomo de oxígeno o azufre, y A representa un anillo de cinco o seis miembros, saturado o insaturado, con uno, dos o tres heteroátomos, o formula (3): -NR11R12 donde R11 y R12 representan independientemente hidrogeno, alquenilo, alquinilo, arilo, heteroarilo o alquilo C1-7, o un heterociclo con 1-3 heteroátomos; Su uso como inhibidores de la produccion de citocinas o mediadores de inflamacion en el tratamiento o profilaxis de cualquier condicion patologica o enfermedad inducida por la produccion excesiva no regulada de citocinas o mediadores de inflamacion, donde se pueden administrar dosis no toxicas de preparaciones farmacéuticas adecuadas en forma oral, parenteral o topica; y procedimientos de preparacion. Particularmente, los compuestos de dibenzoazuleno representados por la formula (1), son utiles, para la inhibicion del factor alfa de necrosis tumoral (TNF-a? y la interleucina 1 (IL-1) en mamíferos en todas aquellas enfermedades y condiciones en las que estos mediadores se excretan en forma excesiva. Los compuestos también demuestran una accion analgésica y pueden ser utilizados para aliviar el dolor.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HR20000310A HRP20000310A2 (en) | 2000-05-17 | 2000-05-17 | New dibenzoazulene compounds as tumor necrosis factor inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR030562A1 true AR030562A1 (es) | 2003-08-27 |
Family
ID=10947110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010102339A AR030562A1 (es) | 2000-05-17 | 2001-05-17 | Derivados de dibenzoazuleno, su uso y procedimientos para prepararlos. |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US6897211B2 (es) |
| EP (1) | EP1284977B1 (es) |
| JP (1) | JP2003533528A (es) |
| KR (1) | KR100823064B1 (es) |
| CN (1) | CN1194976C (es) |
| AR (1) | AR030562A1 (es) |
| AT (1) | ATE434619T1 (es) |
| AU (2) | AU2001256560B2 (es) |
| BG (1) | BG65967B1 (es) |
| BR (1) | BR0111202A (es) |
| CA (1) | CA2409090C (es) |
| CR (1) | CR6860A (es) |
| CY (1) | CY1109328T1 (es) |
| CZ (1) | CZ301770B6 (es) |
| DE (1) | DE60139070D1 (es) |
| DK (1) | DK1284977T3 (es) |
| DZ (1) | DZ3357A1 (es) |
| EA (1) | EA006069B1 (es) |
| EE (1) | EE200200636A (es) |
| ES (1) | ES2328335T3 (es) |
| GE (1) | GEP20043304B (es) |
| HR (1) | HRP20000310A2 (es) |
| HU (1) | HUP0302295A3 (es) |
| IL (1) | IL152809A0 (es) |
| IS (1) | IS6621A (es) |
| MA (1) | MA27125A1 (es) |
| MX (1) | MXPA02011269A (es) |
| NO (1) | NO20025510L (es) |
| NZ (1) | NZ522553A (es) |
| PL (1) | PL204849B1 (es) |
| PT (1) | PT1284977E (es) |
| RS (1) | RS50893B (es) |
| SI (1) | SI1284977T1 (es) |
| SK (1) | SK17702002A3 (es) |
| WO (1) | WO2001087890A1 (es) |
| ZA (1) | ZA200209180B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20020303B8 (en) | 2002-04-10 | 2009-03-31 | GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. | Benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| HRP20020305A8 (en) * | 2002-04-10 | 2009-03-31 | GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. | 2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| HRP20020304B1 (en) | 2002-04-10 | 2008-04-30 | GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. | 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof |
| HRP20020441A2 (en) * | 2002-05-21 | 2003-12-31 | Pliva D D | 1-oxa-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof |
| HRP20020440B1 (en) * | 2002-05-21 | 2008-02-29 | GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. | 1-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof |
| HRP20020453A2 (en) | 2002-05-23 | 2003-12-31 | Pliva D D | 1,3-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof |
| HRP20020452A2 (en) * | 2002-05-23 | 2004-02-29 | Pliva D D | 1,2-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediates for preparation thereof |
| HRP20020451A2 (en) | 2002-05-23 | 2003-12-31 | Pliva D D | 1-tia-3-aza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediates for preparation thereof |
| HRP20030160A2 (en) * | 2003-03-06 | 2005-04-30 | Pliva-Istra�iva�ki institut d.o.o. | 1-thiadibenzoazulene derivatives and biological action thereof |
| HRP20030324A2 (en) | 2003-04-24 | 2005-02-28 | Pliva-Istra�iva�ki institut d.o.o. | Compounds of antiinflammatory effect |
| US20090018351A1 (en) * | 2003-11-12 | 2009-01-15 | Dr. Reddy's Laboratories, Inc. | Preparation of escitalopram |
| HRP20030955A2 (en) * | 2003-11-21 | 2005-08-31 | Pliva-Istra�iva�ki institut d.o.o. | USE OF 1-OXADIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS |
| HRP20030954A2 (en) * | 2003-11-21 | 2005-08-31 | Pliva D.D. | USE OF 1-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS |
| HRP20040104A2 (en) * | 2004-01-30 | 2005-10-31 | Pliva-Istra�iva�ki institut d.o.o. | Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders |
| CN101090908A (zh) | 2004-10-27 | 2007-12-19 | 葛兰素伊斯特拉齐瓦基森塔萨格勒布公司 | 具有抗炎活性的共轭物 |
| AU2005313325C1 (en) * | 2004-12-07 | 2011-11-10 | Janssen Pharmaceutica N.V. | Substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives |
| EP1844053A2 (en) * | 2005-01-13 | 2007-10-17 | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. | Anti-inflammatory macrolide conjugates |
| WO2007103540A2 (en) | 2006-03-08 | 2007-09-13 | Pharmena North America Inc. | Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries |
| US8389482B2 (en) | 2007-01-30 | 2013-03-05 | New York University | Short peptides useful for treatment of ischemia/reperfusion injury and other tissue damage conditions associated with nitric oxide and its reactive species |
| WO2008096755A1 (ja) * | 2007-02-07 | 2008-08-14 | Nippon Suisan Kaisha, Ltd. | バニロイド受容体（ｖｒ１）阻害剤及びその用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3711489A (en) * | 1971-03-31 | 1973-01-16 | Pfizer | Certain 8,9-dihydro(3,4,7,8)cycloocta(1,2-d)imidazoles |
| JPS53116385A (en) * | 1977-03-19 | 1978-10-11 | Hokuriku Pharmaceutical | Pyrazin derivative and method for its production |
| US4198421A (en) * | 1978-11-30 | 1980-04-15 | E. I. Du Pont De Nemours And Company | Antiinflammatory 2-substituted-dibenzo[2,3:6,7]oxepino[4,5-d]imidazoles |
| CA2232141C (en) * | 1996-04-12 | 2006-05-23 | Janssen Pharmaceutica N.V. | Substituted tetracyclic tetrahydrofuran derivatives |
| GB9713368D0 (en) * | 1997-06-25 | 1997-08-27 | Weston Medical Ltd | Flame control |
| EP0887339A1 (de) * | 1997-06-27 | 1998-12-30 | Roche Diagnostics GmbH | Neue Azulenderivate und diese enthaltende Arzneimittel |
-
2000
- 2000-05-17 HR HR20000310A patent/HRP20000310A2/hr not_active Application Discontinuation
-
2001
- 2001-05-16 DZ DZ013357A patent/DZ3357A1/fr active
- 2001-05-16 DK DK01929882T patent/DK1284977T3/da active
- 2001-05-16 DE DE60139070T patent/DE60139070D1/de not_active Expired - Lifetime
- 2001-05-16 IL IL15280901A patent/IL152809A0/xx unknown
- 2001-05-16 WO PCT/HR2001/000027 patent/WO2001087890A1/en not_active Ceased
- 2001-05-16 BR BR0111202-3A patent/BR0111202A/pt not_active Application Discontinuation
- 2001-05-16 PT PT01929882T patent/PT1284977E/pt unknown
- 2001-05-16 RS YUP-841/02A patent/RS50893B/sr unknown
- 2001-05-16 CA CA2409090A patent/CA2409090C/en not_active Expired - Fee Related
- 2001-05-16 PL PL365054A patent/PL204849B1/pl not_active IP Right Cessation
- 2001-05-16 SK SK1770-2002A patent/SK17702002A3/sk unknown
- 2001-05-16 JP JP2001584284A patent/JP2003533528A/ja active Pending
- 2001-05-16 AT AT01929882T patent/ATE434619T1/de not_active IP Right Cessation
- 2001-05-16 ES ES01929882T patent/ES2328335T3/es not_active Expired - Lifetime
- 2001-05-16 EP EP01929882A patent/EP1284977B1/en not_active Expired - Lifetime
- 2001-05-16 EA EA200201223A patent/EA006069B1/ru not_active IP Right Cessation
- 2001-05-16 NZ NZ522553A patent/NZ522553A/en unknown
- 2001-05-16 GE GE5019A patent/GEP20043304B/en unknown
- 2001-05-16 HU HU0302295A patent/HUP0302295A3/hu unknown
- 2001-05-16 EE EEP200200636A patent/EE200200636A/xx unknown
- 2001-05-16 MX MXPA02011269A patent/MXPA02011269A/es active IP Right Grant
- 2001-05-16 SI SI200130930T patent/SI1284977T1/sl unknown
- 2001-05-16 AU AU2001256560A patent/AU2001256560B2/en not_active Ceased
- 2001-05-16 CN CNB018115896A patent/CN1194976C/zh not_active Expired - Fee Related
- 2001-05-16 CZ CZ20024090A patent/CZ301770B6/cs not_active IP Right Cessation
- 2001-05-16 AU AU5656001A patent/AU5656001A/xx active Pending
- 2001-05-16 KR KR1020027015567A patent/KR100823064B1/ko not_active Expired - Fee Related
- 2001-05-17 AR ARP010102339A patent/AR030562A1/es active IP Right Grant
-
2002
- 2002-11-11 MA MA26901A patent/MA27125A1/fr unknown
- 2002-11-12 ZA ZA200209180A patent/ZA200209180B/en unknown
- 2002-11-14 IS IS6621A patent/IS6621A/is unknown
- 2002-11-15 NO NO20025510A patent/NO20025510L/no not_active Application Discontinuation
- 2002-11-18 US US10/298,217 patent/US6897211B2/en not_active Expired - Fee Related
- 2002-12-17 BG BG107399A patent/BG65967B1/bg unknown
- 2002-12-17 CR CR6860A patent/CR6860A/es not_active Application Discontinuation
-
2005
- 2005-03-25 US US11/090,743 patent/US20050171091A1/en not_active Abandoned
-
2009
- 2009-08-20 CY CY20091100888T patent/CY1109328T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR030562A1 (es) | Derivados de dibenzoazuleno, su uso y procedimientos para prepararlos. | |
| AR043528A1 (es) | Inhibidores de citoquinas | |
| AR039112A1 (es) | Inhibidores de quinasas | |
| PE20250021A1 (es) | Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8 | |
| AR036029A1 (es) | Derivados de fenilurea sustituidos con carbonamida, procedimiento para preparacion, medicamentos y su empleo para la preparacion de medicamentos para el tratamiento de la diabetes tipo ii | |
| PE20250674A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| CL2012001699A1 (es) | Compuestos derivados de n-(1h-indazol-4-il)imidazo[1,2-a]piridin-3-carboxamida sustituidos, inhibidores de cfms; proceso de preparacion; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento de enfermedades relacionadas con huesos, cancer, trastornos autoinmunes, enfermedades inflamatorias, entre otras. | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR009985A1 (es) | Aminotiofencarboxamidas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| ECSP099706A (es) | Nuevos derivados de n-(8-heteroariltetrahidronaftalen-2yl) y n-(5-heteroarilcroman-3-il) carboxamida para el tratamiento del dolor | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR048340A1 (es) | Compuestos de acido alfa aril o heteroaril metil beta piperidino propanoico como antagonistas del receptor orl1, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para tratar enfermedades mediadas por orl1. | |
| AR038686A1 (es) | Formulaciones de derivados de androstano y agonistas del adrenoreceptor beta 2 antiinflamatorios | |
| AR039256A1 (es) | Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos | |
| AR123435A1 (es) | Derivados de sulfamoil urea que contienen resto alquilo-oxacicloalquilo, y usos de los mismos | |
| UY40235A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| AR053554A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
| RU2009102270A (ru) | Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
| PE20251183A1 (es) | Inhibidores de amida heterociclica biciclica de sodio activado por voltaje 1.8 (nav 1.8) para el tratamiento del dolor | |
| AR130254A1 (es) | Inhibidores de metanógenos | |
| AR043186A1 (es) | Indozolamidas dotadas de actividad analgesica, metodo de preparacion de las mismas y compuesto farmaceutico que las comprende | |
| AR038197A1 (es) | Acidos 3-(imidazolil)-2-alcoxipropanoicos, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y uso de los mismos en la preparacion de medicamentos | |
| AR029302A1 (es) | Compuesto de fenilo 1,4-sustituido, el uso del mismo para la manufactura de un medicamento, agente de diagnostico, composicion farmaceutica que lo contiene y proceso para su preparacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |